Seres Therapeutics Inc. (MCRB)
NASDAQ: MCRB
· Real-Time Price · USD
18.90
-0.49 (-2.53%)
At close: Sep 25, 2025, 3:59 PM
18.90
0.00%
After-hours: Sep 25, 2025, 04:10 PM EDT
-2.53% (1D)
| Bid | 18.3 |
| Market Cap | 165.46M |
| Revenue (ttm) | 5.96M |
| Net Income (ttm) | 85.97M |
| EPS (ttm) | -6.79 |
| PE Ratio (ttm) | -2.78 |
| Forward PE | -1.72 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 19.9 |
| Volume | 64,408 |
| Avg. Volume (20D) | 182,276 |
| Open | 19.03 |
| Previous Close | 19.39 |
| Day's Range | 18.42 - 19.90 |
| 52-Week Range | 6.53 - 24.66 |
| Beta | 0.16 |
| Ex-Dividend Date | n/a |
About MCRB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MCRB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MCRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsSeres Therapeutics Inc. is scheduled to release its earnings on
Nov 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-10.54%
Seres Therapeutics shares are trading lower follow...
Unlock content with
Pro Subscription
4 months ago
-16.04%
Seres Therapeutics shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.
1 month ago · fool.com
Seres (MCRB) Q2 Loss Narrows 34%Seres (MCRB) Q2 Loss Narrows 34%
1 month ago · seekingalpha.com
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughSeres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce ...